A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

Inclusion Criteria:

• Adults 21-50 years of age

• Active Crohn's disease not in remission based on a CDAI score >150

• Willing to take isolated Xanthohumol as a dietary supplement for 8 weeks

• Willing to have blood drawn bi-weekly and fast for 10-12 hours before blood draws

• Willing and able to collect bi-weekly stool samples at home

• Willing and able to collect a 24-hour urine sample before each study visit

• Able to speak, read and understand English

• Must be able to provide written informed consent

• Non-smokers (including tobacco and Cannabis products, combusted or vaporized)

• For individuals of child-bearing potential, willingness to use an intrauterinedevice (IUD) or two other concurrent forms of birth control (e.g., 2 of thefollowing categories: condoms, spermicide-containing gels, films or sponges; and/orvaginal rings) to prevent pregnancy while enrolled

Exclusion Criteria:

• Highly variable dosing of anti-inflammatory medications (dose changes more than 1xper week)

• Currently or recent (within last 14 days) taking any dietary supplements containingxanthohumol, flavonoids, or other known "anti-inflammatories" including: curcumin,turmeric, fenugreek, hops, rosemary, ginger, white willow, devil's claw, fish oil (doses>1 g/day), or quercetin. Candidates will be given the option to "wash out" for 14 days and re-contact the study team.

• Consumption of more than 1 beer per day.

• Currently receiving intravenous nutrition support therapy (or within the last 14days)

• Currently taking anti-coagulant or anti-platelet prescription medications (or theywere taken within the last 14 days)

• Currently taking antibiotic, antiparasitic, or antifungal medications orally orintravenously (or they were taken within the last 14 days)

• Initiation of or changes to supplements or medications within 14 days prior toscreening.

• Initiation of or changes to an exercise regimen within 14 days prior to screening.

• Initiation of or changes to a food plan within 14 days prior to screening.

• Current involvement or within 14 days prior to screening of a significant diet orweight loss program (such as NutriSystem, Jenny Craig, Atkin's or other low-carbdiet programs) or very low-calorie liquid diet programs (such as Optifast, Medifast,and/or HMR)

• Hospitalization (for any reason other than a scheduled medical procedure) within 3months prior to screening

• Gastrointestinal surgery within 3 months prior to screening

• Malignancy within the last 5 years (with the exception of basal cell carcinoma,squamous cell carcinoma, and/or carcinoma in situ of the cervix)

• Women who are lactating, pregnant or planning pregnancy within the next four months

• Typical intake of more than 2 alcohol-containing beverages per day, more than 14 perweek, or more than 4 in any single day within the past 14 days.

• Smoking tobacco or nicotine products (combusted or vaporized)

• Use of illicit drugs/substances (such as but not limited to cocaine, phencyclidine (PCP), and methamphetamine) within 14 days of screening

• Use of inhaled or ingested Cannabis products, including Cannabidiol (CBD)

• Currently participating in another interventional research study, or participated inanother interventional research study within 14 days of screening

• Do not have an active primary care provider or specialist (i.e., gastroenterologist)managing their CD